-
公开(公告)号：US12163153B2
公开(公告)日：2024-12-10
申请号：US16857394
申请日：2020-04-24
Applicant: ALLOGENE THERAPEUTICS, INC.
IPC: C12N5/00 , A61K35/17 , C12N5/0783
Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).
-
Patent Agency Ranking
公开(公告)号：US11781248B2
公开(公告)日：2023-10-10
申请号：US16900602
申请日：2020-06-12
Applicant: ALLOGENE THERAPEUTICS, INC.
Inventor： Thomas Charles Pertel , Barbra Johnson Sasu
CPC classification number: C40B40/10 , C07K16/40 , C12N15/63 , C07K2317/565
Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
-
公开(公告)号：US11896617B2
公开(公告)日：2024-02-13
申请号：US16857573
申请日：2020-04-24
Applicant: ALLOGENE THERAPEUTICS, INC.
Inventor： Thomas Charles Pertel , Barbra Johnson Sasu , Mark W. Leonard
IPC: C12N15/62 , A61K35/17 , A61P35/00 , C07K14/705 , C07K16/28 , C12N5/0783 , A61K39/00
CPC classification number: A61K35/17 , A61P35/00 , C07K14/70517 , C07K14/70596 , C07K16/2803 , C12N5/0636 , A61K2039/505 , C07K2317/76 , C07K2319/33 , C12N2510/00 , C12N2740/15043
Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.
-
公开(公告)号：US11732041B2
公开(公告)日：2023-08-22
申请号：US16851691
申请日：2020-04-17
Applicant: ALLOGENE THERAPEUTICS, INC.
Inventor： Thomas Charles Pertel , Barbra Johnson Sasu , Tao Sai
CPC classification number: C07K16/2803 , A61K35/17 , C07K16/4241 , C07K2317/565 , C07K2317/622 , C07K2317/92
Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.
-
公开(公告)号：US20220033462A1
公开(公告)日：2022-02-03
申请号：US17385805
申请日：2021-07-26
Applicant: ALLOGENE THERAPEUTICS, INC. , CELLECTIS
Inventor： ARVIND RAJPAL , Shobha Chowdary Potluri , Laurent Poirot , Alexandre Juillerat , Thomas Charles Pertel , Donna Marie Stone , Barbra Johnson Sasu
IPC: C07K14/705 , C07K16/30 , A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783
Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
-
公开(公告)号：US11072644B2
公开(公告)日：2021-07-27
申请号：US15525906
申请日：2015-11-09
Applicant: ALLOGENE THERAPEUTICS, INC. , CELLECTIS
Inventor： Arvind Rajpal , Shobha Chowdary Potluri , Laurent Poirot , Alexandre Juillerat , Thomas Charles Pertel , Donna Marie Stone , Barbra Johnson Sasu
IPC: C07K14/705 , C07K16/30 , A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783 , A61K39/00
Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
